ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Insights from 2024 ASCO® GU Annual Meeting

E. Efstathiou

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

Cancer Screening Molecular Tools

Fengting Yan

Aggressive Variant Prostate Cancer: Definition, Diagnosis, Treatment…

Ana Aparicio

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

Yale Cancer Center

I. Kim

AUA Advanced Prostate Cancer Guidelines: 2023 Update

Robert Dreicer

ASCO® 2024 Prostate Cancer Take-Home Messages

2024 ASCO® Annual Meeting Insights Hub

E. Efstathiou

Testosterone Suppression and Recovery in Patients With Advanced Pros…

Benjamin L. Maughan

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

2024 ESMO Annual Meeting Insights Hub

R. Dreicer

ASCO® 2024 Summary: "Prostate Cancer Highlights"

2024 ASCO® Annual Meeting Insights Hub

N. Reizine, K. Tawagi

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Total Health

M. Reimers

Precision Therapies for Prostate Cancer

University of Miami Sylvester Comprehensive Cancer Center

M. Bilusic

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Total Health

S. Kazmi

GnRH Agonists vs. Antagonists in Prostate Cancer

Patrick Campbell

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence for Or…

2024 ASCO® Annual Meeting Insights Hub

J. Hafron

ASCO® 2023 Insights: "PSMAddition - A Phase 3 Trial to Compare Treat…

Insights from 2023 ASCO® Annual Meeting

S. Tagawa

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

Enhanced Diagnostics in Prostate Cancer: PSA and Beyond in 2024

Penn Medicine Abramson Cancer Center

D. Lee